Amgen: Diabetes Mellitus, Type 2 trials

The registry lists 16 Diabetes Mellitus, Type 2 studies with Amgen as lead sponsor. 3 are open to participants now and 1 have results posted.

Phase 1 5Phase 2 6Phase 3 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 DiabetesNot yet recruitingNCT07866066Phase 3
• Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)RecruitingNCT07684144Phase 3
• A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes MellitusRecruitingNCT07590193Phase 1
• Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed DyslipidemiaCompletedNCT02739984Phase 3Results posted
• A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes MellitusActive, not recruitingNCT07160257Phase 1
• Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity DiseaseActive, not recruitingNCT06987695Phase 3
• Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightActive, not recruitingNCT06858878Phase 3
• A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)Active, not recruitingNCT06660173Phase 2
• Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes MellitusCompletedNCT05669599Phase 2
• Multiple Ascending Dose Study in Subjects With Type 2 DiabetesTerminatedNCT01856881Phase 1
• Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus SubjectsTerminatedNCT01755442Phase 1
• Single Ascending Dose Trial in Patients With Type 2 DiabetesTerminatedNCT01492465Phase 1
• A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic NephropathyCompletedNCT01447147Phase 2
• A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and AlbuminuriaCompletedNCT01440257Phase 2
• A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes MellitusCompletedNCT01028963Phase 2
• A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes MellitusWithdrawnNCT00661921Phase 2